Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027131 · ClinicalTrials.gov registry record · Phase 1
Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70
A Phase 1 study, sponsored by UConn Health.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00027131: Clinical Trial Phase 1 study, sponsored by UConn Health.
NCT00027131 is a Phase 1 study that was terminated before completion, run by UConn Health. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00027131, a Phase 1 study, was terminated before completion, sponsored by UConn Health.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Description: The trial is designed to determine the response of the immune system of patients with breast cancer to a vaccine made from their own tumor. Researchers believe that this particular vaccine, which is made from purified heat shock proteins taken from each patient's tumor, might alert the body's immune system to recognize and attack invading cancer. To be considered potentially eligible for this study you must be a high risk breast cancer patient and have a tumor that can be removed surgically. Length/Duration: Vaccinations are administered weekly for six weeks. Follow up visits to the clinic are every three months for two years, then every six months thereafter.
Interventions
- BIOLOGICAL Heat Shock Protein 70-peptide complexes (HSP70)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2000-12 |
| Est. Completion | 2002-10 |
| Phase | Phase 1 |
Why NCT00027131 stopped before completion
NCT00027131 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 1 intervention - of which Heat Shock Protein 70-peptide complexes (HSP70) is the first listed.
NCT00027131 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00027131 about?
NCT00027131 is a clinical study titled "Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70". Description: The trial is designed to determine the response of the immune system of patients with breast cancer to a vaccine made from their own tumor. Researchers believe that this particular vaccine, which is made from purified heat shock proteins taken from each patient's tumor, might alert the ...
What is the current status of trial NCT00027131?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2000-12. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00027131?
The interventions under investigation include: Heat Shock Protein 70-peptide complexes (HSP70) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00027131?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00027131's enrollment target sits among peer trials
15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia